They showed that HER2-specific EXO-T-stimulated cytotoxic T lymphocytes (CTLs) showed potent therapeutic effect against both T47D, an HER2+ breast cancer cell line, and BT474, a trastuzumab-resistant HER2+ breast cancer cell line, in athymic nude mice [442]. The gene discussed is ERBB2; the disease is breast cancer.